Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPICE: Fondaparinux 1.5 mg/day in Renal Impairment
NCT00555438Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2007
- Primary completion
- Oct 2008
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fondaparinux in venous thromboembolism (VTE), sponsored by CHU Saint-Etienne. Primary endpoint: Number of Patients With Major Bleedings at 10 days. Started Jun 2007; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00555438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555438.